# IVAC MUTANOME Phase I Clinical Trial

> **NCT02035956** · PHASE1 · COMPLETED · sponsor: **BioNTech RNA Pharmaceuticals GmbH** · enrollment: 15 (actual)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** IVAC MUTANOME, RBL001/RBL002

## Key facts

- **NCT ID:** NCT02035956
- **Lead sponsor:** BioNTech RNA Pharmaceuticals GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12
- **Primary completion:** 2017-02-14
- **Final completion:** 2019-10
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2020-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02035956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02035956, "IVAC MUTANOME Phase I Clinical Trial". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02035956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*